Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study-Reference-Cited by-同舟云学术

Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study

Published:2017-07 Issue:7 Volume:4 Page:e317-e324
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Harrison Claire N,Schaap Nicolaas,Vannucchi Alessandro M,Kiladjian Jean-Jacques,Tiu Ramon V,Zachee Pierre,Jourdan Eric,Winton Elliott,Silver Richard T,Schouten Harry C,Passamonti Francesco,Zweegman Sonja,Talpaz Moshe,Lager Joanne,Shun Zhenming,Mesa Ruben A

Publisher

Elsevier BV

Subject

Hematology

Reference20 articles.

1. How I treat myelofibrosis;Cervantes;Blood,2014

2. Molecular basis of myelodysplastic/myeloproliferative neoplasms;Reiter;Haematologica,2009

3. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2;Nangalia;N Engl J Med,2013

4. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis;Verstovsek;N Engl J Med,2012

5. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis;Harrison;N Engl J Med,2012

Cited by 258 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. JAK inhibitor selectivity: new opportunities, better drugs?;Nature Reviews Rheumatology;2024-09-09

2. SOHO State of the Art Updates and Next Questions | Choosing and Properly Using a JAK Inhibitor in Myelofibrosis;Clinical Lymphoma Myeloma and Leukemia;2024-09

3. Would you like to take some more ruxolitinib after your fedratinib?;British Journal of Haematology;2024-08-14

4. Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis Aged 70 Years or Older: A Study from the German Registry for Stem Cell Transplantation;Transplantation and Cellular Therapy;2024-08

5. Transfusion-related cost offsets and time burden in patients with myelofibrosis on momelotinib vs. danazol from MOMENTUM;Future Oncology;2024-07-29